{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:48:41Z","timestamp":1769028521397,"version":"3.49.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Vancomycin was introduced nearly 65 years ago and remains the standard antibiotic for serious methicillin-resistant Staphylococcus aureus (MRSA) infections. Staphylococcus aureus remains highly susceptibility to vancomycin (&amp;gt;97%). Despite this, MRSA treatment failure with vancomycin is high in complicated bacteremia. Additionally, vancomycin can cause nephrotoxicity, leading to new therapeutic drug monitoring guidance. This demonstrates how difficult it is to dose vancomycin in a way that is both efficacious and safe, especially during long courses of therapy. Often underappreciated are the cost, resources, and complexity of vancomycin care at a time when alternative antibiotics are becoming cost comparable. This perspective highlights a bigger picture of how the treatment repertoires of many other diseases have changed and advanced since vancomycin\u2019s introduction in the 1950s, yet the vancomycin MRSA treatment standard remains. While vancomycin can still have a role, 65 years may be a practical retirement age for vancomycin in highly complex endovascular infections.<\/jats:p>","DOI":"10.1093\/ofid\/ofac137","type":"journal-article","created":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T18:11:42Z","timestamp":1649527902000},"source":"Crossref","is-referenced-by-count":24,"title":["Approaching 65 Years: Is It Time to Consider Retirement of Vancomycin for Treating Methicillin-Resistant <i>Staphylococcus aureus<\/i> Endovascular Infections?"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5012-5993","authenticated-orcid":false,"given":"Warren","family":"Rose","sequence":"first","affiliation":[{"name":"School of Pharmacy, University of Wisconsin\u2013Madison, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Volk","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Wisconsin\u2013Madison, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J","family":"Dilworth","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Advocate Aurora Health, Milwaukee, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6063-6217","authenticated-orcid":false,"given":"George","family":"Sakoulas","sequence":"additional","affiliation":[{"name":"Division of Host-Microbe Systems and Therapeutics, Center for Immunity, Infection and Inflammation, University of California, San Diego School of Medicine, La Jolla, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,4,9]]},"reference":[{"key":"2022042703251917100_CIT0001","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1001\/jama.293.24.3012","article-title":"Staphylococcus aureus endocarditis: a consequence of medical progress.","volume":"293","author":"Fowler","year":"2005","journal-title":"JAMA"},{"key":"2022042703251917100_CIT0002","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association.","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"2022042703251917100_CIT0003","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jama.2020.0103","article-title":"Effect of vancomycin or daptomycin with vs without an antistaphylococcal beta-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial.","volume":"323","author":"Tong","year":"2020","journal-title":"JAMA"},{"key":"2022042703251917100_CIT0004","doi-asserted-by":"crossref","first-page":"12689","DOI":"10.1038\/s41598-020-69058-z","article-title":"Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.","volume":"10","author":"Shariati","year":"2020","journal-title":"Sci Rep"},{"key":"2022042703251917100_CIT0005","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/cid\/ciu583","article-title":"Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy.","volume":"59","author":"Kullar","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2022042703251917100_CIT0006","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/infdis\/jis552","article-title":"Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia.","volume":"206","author":"Rose","year":"2012","journal-title":"J Infect Dis"},{"key":"2022042703251917100_CIT0007","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1473-3099(20)30447-3","article-title":"Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study.","volume":"20","author":"Kuehl","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2022042703251917100_CIT0008","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/cid\/ciz257","article-title":"Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes.","volume":"70","author":"Minejima","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022042703251917100_CIT0009","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/cid\/cix1127","article-title":"Busting the myth of \u201cstatic vs cidal\u201d: a systemic literature review.","volume":"66","author":"Wald-Dickler","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2022042703251917100_CIT0010","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40121-017-0148-z","article-title":"The safety and economic impact of cefazolin versus nafcillin for the treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections.","volume":"6","author":"Flynt","year":"2017","journal-title":"Infect Dis Ther"},{"key":"2022042703251917100_CIT0011","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/cid\/ciaa653","article-title":"The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study.","volume":"73","author":"Chua","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022042703251917100_CIT0012","first-page":"157","article-title":"Is a reported penicillin allergy sufficient grounds to forgo the multidimensional antimicrobial benefits of beta-lactam antibiotics?","volume":"68","author":"Sakoulas","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022042703251917100_CIT0013","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"2022042703251917100_CIT0014","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1128\/AAC.00227-16","article-title":"Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections.","volume":"60","author":"Claeys","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022042703251917100_CIT0015","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1093\/cid\/ciaa1572","article-title":"Comparative effectiveness of switching to daptomycin versus remaining on vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections.","volume":"72","author":"Schweizer","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022042703251917100_CIT0016","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","article-title":"Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration &gt;1 mg\/L: a matched cohort study.","volume":"56","author":"Murray","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2022042703251917100_CIT0017","doi-asserted-by":"crossref","first-page":"ofx084","DOI":"10.1093\/ofid\/ofx084","article-title":"Ceftaroline for severe methicillin-resistant Staphylococcus aureus infections: a systematic review.","volume":"4","author":"Cosimi","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2022042703251917100_CIT0018","doi-asserted-by":"crossref","first-page":"ofab606","DOI":"10.1093\/ofid\/ofab606","article-title":"Multicenter cohort study of ceftaroline versus daptomycin for treatment of methicillin-resistant Staphylococcus aureus bloodstream infection.","volume":"9","author":"Zasowski","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2022042703251917100_CIT0019","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s42003-021-02339-z","article-title":"Environmental conditions dictate differential evolution of vancomycin resistance in Staphylococcus aureus.","volume":"4","author":"Machado","year":"2021","journal-title":"Commun Biol"},{"key":"2022042703251917100_CIT0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ebiom.2017.05.026","article-title":"Correcting a fundamental flaw in the paradigm for antimicrobial susceptibility testing.","volume":"20","author":"Ersoy","year":"2017","journal-title":"EBioMedicine"},{"key":"2022042703251917100_CIT0021","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/cid\/ciz460","article-title":"The emperor\u2019s new clothes: prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with methicillin-resistant Staphylococcus aureus bloodstream infections (PROVIDE).","volume":"70","author":"Lodise","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022042703251917100_CIT0022","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1128\/AAC.00173-11","article-title":"Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients.","volume":"55","author":"Minejima","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2022042703251917100_CIT0023","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/cpt.726","article-title":"The nephrotoxicity of vancomycin.","volume":"102","author":"Filippone","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2022042703251917100_CIT0024","volume-title":"Vancomycin [package insert]","year":"2017"},{"key":"2022042703251917100_CIT0025","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/0897190014546836","article-title":"Aminoglycoside-induced nephrotoxicity.","volume":"27","author":"Wargo","year":"2014","journal-title":"J Pharm Pract"},{"key":"2022042703251917100_CIT0026","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/dmd.112.049569","article-title":"Organic anion transporter 3 interacts selectively with lipophilic beta-lactam antibiotics.","volume":"41","author":"Wolman","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"2022042703251917100_CIT0027","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"2022042703251917100_CIT0028","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1093\/jac\/dkab278","article-title":"Impact of a vancomycin loading dose on the achievement of target vancomycin exposure in the first 24 h and on the accompanying risk of nephrotoxicity in critically ill patients.","volume":"76","author":"Hodiamont","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2022042703251917100_CIT0029","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2022042703251917100_CIT0030","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6809e1","article-title":"Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections\u2014United States.","volume":"68","author":"Kourtis","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022042703251917100_CIT0031","first-page":"1021","article-title":"Public health importance of invasive methicillin-sensitive Staphylococcus aureus infections: surveillance in 8 US counties, 2016.","volume":"70","author":"Jackson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022042703251917100_CIT0032","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis.","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2022042703251917100_CIT0033","doi-asserted-by":"crossref","first-page":"625","DOI":"10.15585\/mmwr.mm6722a2","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections among persons who inject drugs\u2014six sites, 2005-2016.","volume":"67","author":"Jackson","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022042703251917100_CIT0034","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.amjms.2021.07.009","article-title":"Recent trends in infective endocarditis among patients with and without injection drug use: an eight-year single center study.","volume":"362","author":"Balda","year":"2021","journal-title":"Am J Med Sci"},{"key":"2022042703251917100_CIT0035","doi-asserted-by":"crossref","first-page":"e675","DOI":"10.1093\/cid\/ciaa1354","article-title":"Vancomycin advanced therapeutic drug monitoring: an exercise in futility or virtuous endeavor to improve drug efficacy and safety?","volume":"72","author":"Dilworth","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022042703251917100_CIT0036","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/AAC.34.5.792","article-title":"Vancomycin pharmacokinetics in burn patients and intravenous drug abusers.","volume":"34","author":"Rybak","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"2022042703251917100_CIT0037","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/cid\/ciab452","article-title":"Current paradigms of combination therapy in methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: does it work, which combination and for which patients?","volume":"73","author":"Rose","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022042703251917100_CIT0038","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1592\/phco.31.6.527","article-title":"High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study.","volume":"31","author":"Kullar","year":"2011","journal-title":"Pharmacotherapy"},{"key":"2022042703251917100_CIT0039","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2334-13-66","article-title":"Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients.","volume":"13","author":"Lai","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2022042703251917100_CIT0040","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ijantimicag.2010.07.011","article-title":"High-dose daptomycin in documented Staphylococcus aureus infections.","volume":"36","author":"Bassetti","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"2022042703251917100_CIT0041","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1128\/AAC.02967-15","article-title":"Evaluation of daptomycin exposure and efficacy and safety endpoints to support risk-versus-benefit considerations.","volume":"60","author":"Bhavnani","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022042703251917100_CIT0042","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2022042703251917100_CIT0043","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.japh.2020.02.025","article-title":"Cost comparison of AUC:MIC- versus trough-based vancomycin monitoring for MRSA bacteremia.","volume":"60","author":"Beccari","year":"2020","journal-title":"J Am Pharm Assoc (2003)"},{"key":"2022042703251917100_CIT0044","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/ajhp\/zxab123","article-title":"Validity of 2020 vancomycin consensus recommendations and further guidance for practical application.","volume":"78","author":"Rybak","year":"2021","journal-title":"Am J Health Syst Pharm"},{"key":"2022042703251917100_CIT0045","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1016\/S0895-7061(97)00016-2","article-title":"Evolution of the treatment of hypertension from the 1940s to JNC V.","volume":"10","author":"Moser","year":"1997","journal-title":"Am J Hypertens"},{"key":"2022042703251917100_CIT0046","doi-asserted-by":"crossref","first-page":"e01816","DOI":"10.1128\/AAC.01816-17","article-title":"Systematic review and meta-analysis of the safety of antistaphylococcal penicillins compared to cefazolin.","volume":"62","author":"Eljaaly","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofac137\/43350347\/ofac137.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/5\/ofac137\/43469826\/ofac137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/5\/ofac137\/43469826\/ofac137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T03:25:58Z","timestamp":1651029958000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac137\/6565985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,9]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac137","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,4,9]]},"article-number":"ofac137"}}